# Nuclide record breast-triple-negative (indication). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/indications/breast-triple-negative/>
  a schema:MedicalCondition ;
  nuclide:kind "indication" ;
  schema:identifier "breast-triple-negative" ;
  schema:name "Triple-negative breast cancer"@en ;
  schema:alternateName "TNBC"@en ;
  schema:description "Triple-negative breast cancer lacks the three commonest treatment targets, so hormone therapy and HER2 drugs do not work against it and treatment rests on chemotherapy, immunotherapy and antibody-drug conjugates. It is more aggressive than most breast cancer and harder to treat once it has spread."@en ;
  schema:url <https://nuclide.cc/indications/breast-triple-negative/> ;
  schema:dateModified "2026-09-23"^^xsd:date ;
  schema:citation <https://www.iarc.who.int/wp-content/uploads/2025/02/pr361_E.pdf>, <https://www.cancer.gov/types/breast/breast-cancer-types/triple-negative>, <https://seer.cancer.gov/statfacts/html/breast.html>, <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-sacituzumab-govitecan-hziy-monotherapy-and-combination-pembrolizumab-first-line>, <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-datopotamab-deruxtecan-dlnk-unresectable-or-metastatic-triple-negative-breast-cancer>, <https://www.merck.com/news/fda-approves-keytruda-pembrolizumab-for-treatment-of-patients-with-high-risk-early-stage-triple-negative-breast-cancer-in-combination-with-chemotherapy-as-neoadjuvant-treatment-then-continued/> ;
  nuclide:tag "breast", "immunotherapy", "trop2" ;
  nuclide:related <https://nuclide.cc/targets/trop2/>, <https://nuclide.cc/technologies/trop2-pet/>, <https://nuclide.cc/technologies/fdg-pet/>, <https://nuclide.cc/drugs/fluoroestradiol-f18/> ;
  nuclide:pipeline <https://nuclide.cc/opportunities/opp-trop2-imaging-heterogeneity/>, <https://nuclide.cc/targets/trop2/>, <https://nuclide.cc/technologies/trop2-pet/>, <https://nuclide.cc/technologies/fdg-pet/> .